Lorazepam
Injection · trading as Ativan
Current Active — Day 2808
Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.
FDA shortage record
- Substance
- Lorazepam
- Brand name
- Ativan
- Manufacturers / suppliers
-
- Hikma Pharmaceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Injection
- Presentation
- Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)
- Route(s)
- INTRAMUSCULAR, INTRAVENOUS
- Therapeutic category
- Neurology
- Package NDC
0641-6003-25- Initially posted
- 09/05/2018
- Days on shortage list
- 2808
- Current FDA status
- Current
- Shortage entries (current dataset)
- 2 records for Lorazepam
Reason and context
Reason reported: Other
Estimated recovery: TBD
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
5fc0e987-61c9-40c4-b0d5-fcea07c8733e). - FDA UNII identifier:
O26FZP769L. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.